Clinical trial NCT05634005: Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
Official title: Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anemia
Thrombocytopenia
Coagulopathy, Mild
Hypofibrinogenemia
Keywords: Transfusion
Clinical Decision Support
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2022-12-01
Enrollment: 1543
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a randomized study design to reduce risk of bias. Alerts will be visible to the experimental ordering provider group, while they will not be visible to the control. Both groups still have access to information about best practices: local clinical transfusion guidelines are available and education on blood transfusion best practices will continue regardless of randomization assignment.


Eligibility criteria: Inclusion Criteria:

- Ordering providers that order at least one blood product in the electronic health record

Exclusion Criteria:

* Any individual without privileges to place an initial order for blood product(s)

Primary outcomes:
measure: Number of blood components transfused that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
Secondary outcomes:
measure: Number of red blood cell components transfused that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of platelet components transfused that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of plasma components transfused that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of cryoprecipitate component pools transfused that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
Other outcomes:
measure: Number of blood components ordered that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of red blood cell components ordered that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of platelet components ordered that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of plasma components ordered that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of cryoprecipitate component pools ordered that met clinical decision support alert criteria
timeFrame: Through study completion, an average of 12 months
measure: Number of blood components transfused
timeFrame: Through study completion, an average of 12 months
measure: Number of red blood cell components transfused
timeFrame: Through study completion, an average of 12 months
measure: Number of platelet components transfused
timeFrame: Through study completion, an average of 12 months
measure: Number of plasma components transfused
timeFrame: Through study completion, an average of 12 months
measure: Number of cryoprecipitate component pools transfused
timeFrame: Through study completion, an average of 12 months
measure: Blood component cost difference between clinical decision support eligible transfusions by study arm
timeFrame: Through study completion, an average of 12 months
Locations:
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
Study officials:
affiliation: University of Utah
name: Ryan Metcalf, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, Carson JL, Cichutek K, De Buck E, Devine D, Fergusson D, Follea G, French C, Frey KP, Gammon R, Levy JH, Murphy MF, Ozier Y, Pavenski K, So-Osman C, Tiberghien P, Volmink J, Waters JH, Wood EM, Seifried E; ICC PBM Frankfurt 2018 Group. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA. 2019 Mar 12;321(10):983-997. doi: 10.1001/jama.2019.0554.